Brought to you by 
AbbVie, Harpoon Therapeutics enter immuno-oncology collaboration; deal expanded to include up to six new targets
02 Nov 2021
Executive Summary
In its first collaboration since its founding in 2015, Harpoon Therapeutics is teaming up with AbbVie Inc. in the area of immuno-oncology therapies.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AbbVie, Harpoon Therapeutics enter immuno-oncology collaboration; deal expanded to include up to six new targets
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice